Cell Biotech Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Aug 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 7, 2027The maintenance fee for Composition for preventing, relieving or treating climacteric disorders comprising lactic acid bacteria and prebiotics (US 11,805,799) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 4 fees due Sep 5 to 29, 2027 · next Sep 5
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,296,987 | Multi-coated lactic acid bacteria and preparing method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,597,740 | Bifidobacterium longum CBT BG7 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,026,983 | Bifidobacterium breve CBT BR3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,596,208 | Composition for preventing or treating obesity or lipid-related metabolic disease In force · From the USPTO record | In force | From the USPTO record | |
| US 11,213,565 | Protein P8 derived from lactic acid bacteria and its use as anti-cancer agent In force · From the USPTO record | In force | From the USPTO record | |
| US 10,835,562 | Composition for Alcohol or Acetaldehyde Degradation Comprising Probiotics In force · High confidence | In force | High confidence | |
| US 11,298,385 | Microorganism for Delivering Drug for Treatment of Gastrointestinal Disease, Which Expresses and Secretes P8 Protein, and Pharmaceutical Composition for Preventing or Treating Gastrointestinal Disease, Which Includes the Same In force · Medium confidence | In force | Medium confidence | |
| US 11,117,953 | Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes cystatin, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,530,414 | Gene Expression Cassette and Expression Vector Including the Same In force · Medium confidence | In force | Medium confidence | |
| US 12,269,850 | Composition for Treating or Preventing Colorectal Disease Containing Construct for Expression of P8 Protein Derived from Lactic Acid Bacteria In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 no status recorded